• Home
  • NEW DAY MEDICINE
  • 12(50)2022
  • 40 -12 (50) 2022 — Amonov Muhammad Komil ugli — THE STUDY OF THE FUNCTIONAL RESERVE OF THE KIDNEYS IN THE COMBINED STATE OF ARTERIAL HYPERTENSION WITH COVID-19.

40 -12 (50) 2022 — Amonov Muhammad Komil ugli — THE STUDY OF THE FUNCTIONAL RESERVE OF THE KIDNEYS IN THE COMBINED STATE OF ARTERIAL HYPERTENSION WITH COVID-19.

THE STUDY OF THE FUNCTIONAL RESERVE OF THE KIDNEYS IN THE COMBINED STATE OF ARTERIAL HYPERTENSION WITH COVID-19.

Amonov Muhammad Komil ugli Bukhara State Medical Institute

Resume

While the clinical syndromes of COVID-19 infection vary greatly between patients, ranging from infection of the middle and upper respiratory tract to critical illness with multiple organ failure, acute kidney injury (AKI) is a common complication of COVID-19 in up to 46% [1,2] AKI is associated with higher mortality in patients with COVID-19,[3] but post-discharge renal function data were not available in a large cohort, and a small study observed a decrease in kidney function in 182 patients with COVID-19 patients with OPP.[4] Because AKI is a clinically significant risk factor for chronic kidney disease (CKD), the long-term post-acute effects of COVID-19-associated AKI require further study. However, to date, there are several key limitations in research on the outcome of kidney function recovery in COVID-19-associated AKI. First, renal function recovery studies lacked adequate pre-hospital serum creatinine levels to quantify renal function decline after AKI [5,6] and may underestimate pre-existing undiagnosed CKD prior to hospitalization for COVID-19. Second, kidney function outcomes in COVID-19-related AKI were defined by either: a) post-discharge kidney function assessments, including estimated glomerular filtration rate (eGFR), which greatly underestimated baseline serum creatinine levels4, or b) clinical measures Serious renal adverse events, including renal replacement therapy (RRT), that underestimate the onset of CKD after an initiating episode of AKI. 7 Finally, follow-up periods in these cohort studies ranged from 3 to 10 months and did not reflect long-term renal dysfunction. more than 1 year after AKI [4–8].

Key words: COVID-19, arterial hypertension, podocyte, nephropathy, functional reserves of the kidneys.

First page

234

Last page

238

For citation: Amonov Muhammad Komil ugli – THE STUDY OF THE FUNCTIONAL RESERVE OF THE KIDNEYS IN THE COMBINED STATE OF ARTERIAL HYPERTENSION WITH COVID-19. //New Day in Medicine 12(50)2022 234-238 https://clck.ru/338MY3

LIST OF REFERENCES:

  1. Amonov Muhammad Komil o’g’li/ Orientation to Acute Kidney Injury in Covid-19/Vol. 1 No. 5 (2021): Journal of Advanced Research and Stability (JARS)
  2. Amonov Muhammad Komil o’g’li/ Risk factors for severe and critical patients with COVID-19/ Oriental Renaissance: Innovative, educational, natural and social sciences/volume 1 | ISSUE 10
  3. Amonov, Muhammad Komil Ogli Risk factors for severe and critical patients with COVID-19 // Orienss. 2021. №10. URL: https://cyberleninka.ru/article/n/risk factors for severe and critical patients with covid-19
  4. Beckerman P., Bi Karchin J., Park A.S., Qiu C., Dummer P.D., Bell R., Herring S.M., Gokul N., Monita M., Grove M.L., Boerwinkle E., Doris P.A. (2011). High resolution identity by descent mapping uncovers the genetic basis for blood pressure differences between spontaneously hypertensive rat lines. Circulation: Cardiovascular Genetics, 4, 223–231.
  5. Brat G.A., Weber G.M., Gehlenborg N. et al. International electronic health record-derived COVID-19 clinical course profiles: the 4CE consortium. NPJ Digit Med. 2020;3(1):109.
  6. Cardarelli F., Bellasi A., Ou F.S. et al. Combined impact of age and estimated glomerular filtration rate on in-hospital mortality after percutaneous coronary intervention for acute myocardial infarction (from the American College of Cardiology National Cardiovascular Data Registry). //Am J Cardiol. 2009;103(6):766–771.
  7. Chan L., Chaudhary K., Saha A. et al. AKI in hospitalized patients with COVID-19. //J Am Soc Nephrol. 2021;32(1):151–160.
  8. Cheng Y., Luo R., Wang K., Zhang M., Wang Z., Dong L. et al. Госпитальная смерть от COVID-19 связанная с заболеваниями почек. //Kidney Int. (2020) 97: 829–38. 10.1016 / j.kint.2020.03.005
  9. Cohen J.B., D’Agostino McGowan L., Jensen E.T., Rigdon J., South A.M. Evaluating sources of bias in observational studies of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use during COVID-19: beyond confounding. //J Hypertens. 2021; 39(4):795–805.
  10. Gu X., Huang L., Cui D. et al. Association of acute kidney injury with 1-year outcome of kidney function in hospital survivors with COVID-19: a cohort study. EBioMedicine. 2022; 76:103817.
  11. Gupta S., Coca S.G., Chan L. et al. AKI treated with renal replacement therapy in critically ill patients with COVID-19. //J Am Soc Nephrol. 2021;32(1):161–176.
  12. Gupta S., Hayek S.S., Wang W. et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med. 2020;180(11):1436–1446.
  13. Hirsch J.S., Ng J.H., Ross D.W. et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020; 98(1):209–218.
  14. Klann J.G., Estiri H., Weber G.M. et al. Validation of an internationally derived patient severity phenotype to support COVID-19 analytics from electronic health record data. //J Am Med Inf Assoc. 2021;28(7):1411–1420.
  15. Lopes R.D., de Barros e Silva PGM, Furtado RHM, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2021; 397(10291):2253–2263.
  16. Lumlertgul N., Pirondini L., Cooney E. et al. Acute kidney injury prevalence, progression and long-term outcomes in critically ill patients with COVID-19: a cohort study. //Ann Intensive Care. 2021; 11(1):123.
  17. Nugent J., Aklilu A., Yamamoto Y. et al. Assessment of acute kidney injury and longitudinal kidney function after hospital discharge among patients with and without COVID-19. //JAMA Netw Open. 2021;4(3):e211095.
  18. Spyropoulos A.C., Goldin M., Giannis D. et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediatedose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. //JAMA Intern Med. 2021;181(12):1612–1620.
  19. Strohbehn I.A., Zhao S., Seethapathy H. et al. Acute kidney injury incidence, recovery, and long-term kidney outcomes among hospitalized patients with COVID-19 and influenza. Kidney Int Rep. 2021;6(10):2565–2574.
  20. Sulaimonova Gulnoza Tulkinjanovna, Jumayeva Madina Fakhriddinovna, Kayumov Laziz Kholmurodovich. Features Of The Course Of Chronic Kidney Disease According To The Degree Of Nephrinuria In A Comorbid State With Hypertension And Diabetes Mellitus. //Texas Journal of Medical Science Vol.3,Date of Publication:05.12.2021, pages 23-26

file

download